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ABSTRACT 
 
Cardiac tissue engineering aims at restoring cell compartment along with 
myocardial extracellular microenvironment. Even though countless combinations 
of synthetic or biological scaffolds and stem/progenitor cells of various origin 
have been tested so far, the most suitable candidate is yet to be found. With the 
aim to develop a natural injectable self-assembling scaffold able to be serve as 
both three-dimensional platform and stem/progenitor cell delivery method, we 
assembled fibrin gels incorporating Cardiac Primitive Cells (CPC) and cardiac 
decellularized extracellular matrix (d-ECM). Cryosections of cardiac ECM were 
decellularized and d-ECM was lyophilized and solubilized. d-ECM solution was 
mixed with the fibrin solution carrying Cardiac Primitive Cells (CPC) isolated 
from adult heart and allowed to gel at 37°C. Several Fibrin to Matrix ratios (F: 
M) were tested to determine the ideal composition in terms of time of gelling and 
three-dimensional (3D) architecture. Gels were cultured for three days, then fixed 
and processed as tissues for histological study. Histochemistry revealed the 
presence of viable CPC in the gels whose architecture varied from densely 
packed to very loose. Due to time of gelling and to concentration of fibrin, the 
distribution of CPC in the scaffold was even only in the gel with F:M of 1:1. 
According to our results, the combination of CPC with fibrin and d-ECM at F:M 
of 1:1, being injectable and self-assembling at body temperature, provides an 
attracting alternate to bioconstructs.  
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1. INTRODUCTION 
 MYOCARDIAL INFARCTION AND HEART FAILURE 1.1
 
Coronary heart disease (CHD) is now the leading cause of death worldwide (1). 
In 2010, CHD caused ∼1 of every 6 deaths in the United States (US) (2). Recent 
data show that death rates from CHD have decreased in North America and in 
many countries in Western Europe (3). This decline has been due to improved 
prevention (reduced cigarette smoking among adults, lower average levels of 
blood pressure and blood cholesterol), diagnosis, and treatment (pharmacological 
or interventional).  
Myocardial infarction (MI) is the most common manifestation of CHD, 
accounting for ~ 50% of all CHD cases in the US (4). Acute myocardial 
infarction (MI), usually known as a heart attack, is triggered by the occlusion of 
one or more of the blood vessels (coronary arteries) supplying blood to the heart. 
Consequently, the supply of nutrients and oxygen to the heart muscle 
(myocardium) is reduced, and leads to a remarkable loss of contractile muscle 
cells (cardiomyocytes). The tissue becomes necrotic and cardiac performance can 
be impaired. In addition, healthy myocytes close to the infarct may also die, 
causing an increase in size of the necrotic tissue area. Furthermore, since 
cardiomyocytes rarely divide, contractile cells cannot repopulate the infarcted 
area, while non-contractile cells (fibroblasts) gradually replace them (5, 6, 7), 
causing the formation of a densely collagenous non-contractile scar (8). All of 
these results in significant alterations in the structure and composition of the 
myocardial extracellular matrix (ECM) (9, 10), in addition to the loss of cellular 
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elements. The post-MI process, that commonly affects the mechanical properties 
of the left ventricle of myocardium, is called left ventricular remodeling (LVR). 
During LVR, the ventricle wall becomes thinner and structural changes, such as 
an increase in left-ventricular volume, occur in the heart (5, 6, 11-14). To block 
the cascade of unfavorable events of MI and restore the original structure of the 
lost cardiac tissue, new cardiomyocytes must replace the lost ones.  
Unfortunately, to date, the problem of how to treat the thousands of patients per 
year worldwide, who survive an extensive myocardial infarction (MI) and 
develop advanced heart failure, has not been resolved, despite optimal medical 
therapy (15). Heart transplant, traditionally, is the best solution for the patients 
with end-stage heart failure. However, donor supply is declining, increasing the 
gap between supply and demand for heart replacement therapies (16). In addition, 
lifelong immune suppression often causes serious complications (17, 18).  
Therefore, it is desirable to develop less invasive alternative therapeutic 
strategies which can promote rapid reconstruction of the affected tissue and 
efficient renewal of its contractile capacity, in order to ameliorate both patient 
prognosis and life quality.  
Different approaches in cell transplantation and cardiac tissue engineering have 
emerged as potential treatments to restore cardiac function (19). 
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 CARDIAC EXTRACELLULAR MATRIX (ECM) 1.2
1.2.1 COMPOSITION AND FUNCTION 
 
Myocardial tissue is composed of cardiomyocytes, non-myocytes (e.g. 
fibroblasts, endothelial cells, vascular smooth muscle cells, etc.), and 
extracellular matrix (ECM) proteins (20-24). The ECM, that refers to the non-
cellular component, constitutes a scaffold for myocytes, fibroblasts, and 
endothelial cells, providing mechanical stability, physical strength, stiffness, 
ductility, and energy absorption to tissues. It is essential for efficient cardiac 
function via myocyte alignment, regulating blood flow during contraction, and 
compliance. Moreover, the ECM is an important mediator of growth-related 
factor and plays an essential role in development, remodeling, and signaling in 
the cardiovascular system. Therefore, the disruption of ECM homeostasis is a 
key factor for the progression of cardiac dysfunction (20). Cellular interactions 
with the ECM are also essential to normal formation of the heart (25-28). 
The ECM, whose composition and architecture varies depending on the native 
tissue, is a three-dimensionally (3D) arranged complex mixture of various 
molecules, such as collagens, glycoproteins (e.g fibronectins, laminins and 
elastins), proteoglycans (PGs) including glycosaminoglycans (GAGs), 
extracellular protease and ECM receptors (integrins) (29). Other important 
components of the extracellular matrix include a family of matrix 
metalloproteinases (MMPs) which guarantee constant extracellular matrix 
remodeling, and growth factors.  
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Although glycoproteins and proteoglycans are essential in proper cardiac 
geometry and for various functions of the ECM, the most abundant structural 
components of the ECM are collagens (21). The ability to synthesize the ECM 
components depends on cell types in the heart. Fibroblasts and smooth muscle 
cells synthesize collagen types I and III, and fibronectin, whereas 
cardiomyocytes and endothelial cell produce collagen type IV. Cardiomyocytes, 
smooth muscle cells, and endothelial cells produce laminin (29).  
 
a) COLLAGENS 
 
Collagen is the most abundant and ubiquitous ECM protein in mammals, which 
is not only critically important for the biomechanical stability of tissues, but is 
also intimately involved in cell adhesion and migration during growth, 
differentiation, morphogenesis and wound healing (30). To date, nearly 30 types 
of collagen have been identified (31). Each protein contains three polypeptide (α) 
chains, displaying an extended polyproline-II conformation, a right-handed 
supercoil and a one-residue stagger between adjacent chains (32). Each 
polypeptide chain has a repeating Gly-X-Y triplet in which glycine residues 
occupy first position and the X and Y positions are frequently occupied by 
proline and 4-hydroxyproline, respectively. These repeats allow the formation of 
a triple helix, which is the characteristic structural feature of the collagen 
superfamily. In the heart, collagen constitutes a relatively small fraction of 
myocardial mass. Nevertheless, the myocardial collagen network is essential to 
the mechanics of the heart (33). The myocardial collagen matrix mainly consists 
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of type I and III collagens, which form a structural continuum. Collagen type I 
fibers mainly provide structural support and give the heart properties that include 
stiffness and resistance to deformation. The collagen type III fibers seem to play 
an important role as a link between contractile elements of adjacent myocytes, 
carrying some information useful for cell function and contributing elasticity (34-
36). The two type of collagens jointly support and tether myocytes in maintaining 
their alignment, tensile strength, shape and thickness in order to prevent rupture 
and contribute to the passive and active stiffness of the myocardium (37).  
 
b) ELASTIN  
 
While collagens provide tissue rigidity, elastin allows many tissues in the body to 
resume their shape after stretching or contracting. 
Elastin is highly hydrophobic, composed primarily of aminoacids such as 
alanine, valine, leucine and glycine (38). It is an insoluble protein generated by 
lysyl oxidase crosslinking of soluble tropoelastin monomers. The elastin tends to 
be located in the inner core of the elastic fiber and is surrounded by a fine mesh 
of microfibrils. These microfibrils are predominantly fibrillin-1, but to a lesser 
extent Fibrillin-2 (39). Myocardium contains elastin, both in the walls of 
coronary blood vessels and in the interstitium, but it is unclear whether elastin 
contributes significantly to myocardial mechanics (40). 
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c) LAMININ 
 
Cell adhesive molecules, such as laminin, are important non-collagenous 
glycoproteins (41, 42).  
Laminin is one of the main components of the basement membrane. Its molecular 
weight is 200-400 kDa and it is composed of three disulphide-linked chains 
which form characteristic cross shape. Laminin is a heterotrimeric glycoprotein 
consisting in one α, one β, and one γ chain, in various combinations (five α, three 
β, and three γ chains). Twelve distinct laminin isoforms have been isolated and 
the trimers are named according to their trimeric composition of α, β, and γ 
chains (43). Laminin-1 (α1β1γ1) is the first extracellular matrix protein to be 
expressed during embryonic development, and it has been observed that the heart 
organogenesis does not proceed in the absence of this protein (44). The absence 
of laminin-2 (α2β1γ1), an isoform typical of muscle tissue, causes congenital 
muscular dystrophy with cardiac involvement (45). Moreover it has been showed 
that, in the adult heart, laminin-1 and laminin-2 protect from apoptosis and 
stimulate proliferation of CPCs in vitro (46). The complex adhesion protein -
laminin mediates cell adhesion, migration, growth and differentiation. Analysis 
of the interaction between basement membrane proteins and cardiomyocytes has 
led to the recognition that laminin is important for the survival of these 
specialized cells in vitro (47).  
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d) FIBRONECTIN 
 
Fibronectin is a dimeric glycoprotein (with the subunits that range in size from 
230 kDa to 270 kDa) found in the extracellular matrix of most tissues. It is 
located within the basement membrane, that serves as a bridge between cells and 
the interstitial collagen meshwork and influences diverse processes including cell 
growth, adhesion, migration, and wound repair (48).  The expression of 
fibronectin is a critical factor in cardiac extracellular matrix, particularly in 
developing myocardium and in response to injury. Fibronectin levels have been 
found to be higher in neonatal hearts when compared to adult. In the 
cardiovascular system, fibronectin is synthesized by many cell types but not by 
the cardiomyocytes. Recently, expression of fibronectin was shown to influence 
cardiac progenitor cell response after myocardial infarction in adult mice (49). 
 
e) PROTEOGLYCANS AND GLYCOSAMINOGLYCANS 
 
Proteoglycans (PGs) and glycosaminoglycans (GAGs) perform numerous vital 
functions within human body. Accordingly, PGs can be considered as one of the 
most critical ECM components for normal cell function and tissue development 
(50). PGs regulate cartilage mechanics by controlling the flow of water in and 
out of the tissue during loading. Azeloglu et al. recently demonstrated that PGs 
are an important determinant of residual stress in arteries, where, as in 
myocardium, their presence had been largely ignored (51). 
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GAGs are polysaccharide chains consisting of repeating amino sugar and uronic 
acid disaccharide units. There are four classes of GAGs. The most abundant 
GAG in the developing heart is hyaluronan (HA) which consists of alternating 
UDP glucuronic acid and UDP-N-acetylglucosamine molecules, which alternate 
to combine in a chain-like fashion (52). HA is part of a pericellular matrix that 
provides a hydrated environment that facilitates cellular proliferation and motility 
(53). The other three classes of GAGs are chondroitin sulfate/dermatan sulfate 
(CS/DS), heparan sulfate/heparin (HS), and keratin sulfate (KS). These GAGs 
are found in the ECM of the heart linked to proteoglycan core proteins (54).  
 
f) INTEGRINS  
 
ECM in the heart is linked to cellular cytoskeleton by transmembrane molecules, 
mainly integrins, which provides a physical connection between cytoskeleton and 
ECM proteins (55, 56). They orchestrate multiple functions in the intact organism 
including organogenesis, regulation of gene expression, cell proliferation, 
differentiation, migration, and death (57). The integrin family consists of a large 
multi-adhesive extracellular matrix molecules that bind different proteins, 
including extracellular matrix molecules, growth factors, cytokines, and MMPs. 
Integrins, heterodimeric type I transmembrane proteins, consist of α and β 
subunits. The family is composed of 18 α subunits and 8 β subunits, that can 
assemble into 24 different heterodimers. The integrins can be grouped based on 
ligand-binding properties or on their subunit composition. In the cardiac 
myocytes, the integrin heterodimers most highly expressed are α1β1, α5β1 and 
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α7β1, which are predominantly collagen, fibronectin and laminin binding 
receptors, respectively (58). They are expressed in all cellular components of the 
cardiovascular system, including the vasculature, blood, cardiac myocytes, and 
non-muscle cardiac cells (25-28). 
 
1.2.2 REMODELLING OF ECM AFTER MYOCARDIAL INFARCTION   
 
The cardiac extracellular matrix is critical to maintain the structural integrity of 
the heart. The disruption of the matrix network results in alterations of the 
ventricular geometry (59-61). Perhaps, the most dramatic changes in the 
composition of the cardiac extracellular matrix occur in the setting of acute 
myocardial infarction. Myocardial infarction ultimately results in replacement of 
dead cardiomyocytes with a collagen-based scar. Cardiac wound repair after MI 
involves cellular and molecular events that can be divided in three overlapping 
phases: inflammatory, proliferative and maturation phase (62).  
Immediately, after a myocardial infarction, cardiomyocytes death triggers 
activation of the complement system, generates free radicals and actives Tall- 
Like Receptor (TRL)-mediated pathway. These overlapping pathways activate 
Nuclear Factor (NF)-kB in resident myocardial cells inducing expression of 
cytokines (such as Tumor Necrosis Factor (TNF)-alfa and IL-1beta), chemokines 
and adhesion molecules (63, 64), initiating the inflammatory phase. The 
activation of the cytokines enhances Matrix Metalloproteinase (MMP) 
expression and activity, promoting cardiac matrix degradation (65, 66). During 
the inflammatory phase, increased permeability of the cardiac microvasculature 
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results in extravasation of fibrinogen and plasma fibronectin, forming a 
provisional matrix network that serves as a scaffold for migration and 
proliferation of infiltrating inflammatory cells (leukocyte), endothelial cells and 
fibroblasts (67). In addition, the fragmentation of extracellular matrix 
constituents during the early stages following infarction, as collagen and low 
molecular weight hyaluronan fragments, exerts potent pro-inflammatory effects 
(68-70). As the professional phagocytes clear the wound from dead cells and 
matrix debris, the activation of “stop signals” (such as Interleukin (IL)-10 and 
Transforming Growth Factor (TGF)-beta) suppress the inflammatory reaction 
leading to transition to the proliferative phase (62). During this phase, the 
plasma-derived provisional matrix is lysed by proteolytic enzymes produced by 
granulation tissue cells, and is replaced by an organized cell-derived provisional 
matrix containing cellular fibronectin and hyaluronan (69). When fibrin and 
plasma fibronectin are cleared from the infarcted area, the cellular fibronectin is 
secreted by fibroblasts and macrophages and serves as a “second order” 
provisional matrix (71). Fibronectin is essential for modulation of fibroblasts 
toward myofibroblasts, an important process for reparative response (72-74). 
Activated myofibroblasts play an important role in wound contraction and are the 
main source of collagen in the healing infarct (75).   
During the proliferative phase, the matricellular proteins play an important role 
as regulators of the reparative response. These proteins are a family of 
structurally diverse extracellular matrix proteins that modulate cell function and 
activity; their induction is a prominent feature of the proliferative phase of 
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healing and appears to play an important role in regulating the dynamic cellular 
events and in promoting matrix organization, in cardiac repair. They include 
thrombospondin (TSP)-1 and -2, tenascin-C and –X, Osteonectin/SPARC 
(secreted protein, acid and rich in cysteine), osteopontin (OPN) and periostin. 
These proteins are not expressed in normal hearts (62). 
Finally, the maturation phase occurs, promoting the formation of a mature scar 
comprised of dense cross-linked collagen, that enhances tensile strength of the 
infarct, and increases the passive stiffness contributing to diastolic dysfunction 
(76). Scar formation is an essential aspect of rapid wound healing without which 
the ischaemic region would be subject to rupture. However, scar tissue is largely 
acellular and lacks the normal biochemical properties of the host cells. This leads 
to electrical uncoupling, mechanical dysfunction, and loss of structural integrity 
(77, 78).  
This post-MI remodeling process is a clinically significant problem in that it can 
lead to LV dilation, systolic and diastolic dysfunction, and the progression to 
heart failure (59). 
The discovery of the proliferative capacity and plasticity of various stem cells 
populations has sparked much interest and debate regarding their use as a 
potential therapy. 
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 CELL BASED THERAPY FOR CARDIAC REPAIR 1.3
 
Hopefully, the regeneration of myocardium after a major insult should involve 
new contracting cardiomyocytes into the infarct zone, which would empower the 
heart contractility after integration with the host tissue. Therefore, the Cardiac 
Cell Therapy (CCT) represents the first realistic strategy for reversing the 
deleterious effects of the terminal damage of the heart. The cell therapy, which 
involves the transplantation of stem cells to replace necrotic cardiomyocytes, 
could have the potential to restore cardiac function by inducing 
neovascularization, and regenerating and protecting cardiomyocytes (79). Stem 
cells are distinguished by two important characteristics: first, they are 
unspecialized cells capable of self-renewing through cell division; second, under 
certain physiologic or experimental conditions, they can be induced to become 
tissue-or organ-specific cells with special functions (80, 81). These two 
properties make stem cells unique and suitable for cardiac repair. The ideal 
source of cells to heart repair would: a) expand in vitro on a large scale b) 
integrate with damaged tissue, and c) differentiate into new cardiomyocytes 
electromechanically coupled with the host tissue (82). Thus, during the last 
decade, several cell types that might replace necrotic tissue and minimize 
scarring have been considered, including skeletal myoblasts (83), bone marrow-
derived haematopoietic stem cells (84), mesenchymal stem cells (85), cardiac 
stem cells (CSCs) (86), embryonic stem cells (ESCs) (87-89), endothelial 
progenitor cells (90), and induced pluripotent stem (iPSc) cells (91).  
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More specifically, skeletal myoblasts have been implanted because they can be 
easily isolated and they have high rate of proliferation and are hypoxia-resistant 
(92, 93). Similarly, different cell populations residing in bone marrow have been 
tested because of their great plasticity towards cells of cardiogenic and 
endothelial lineage (94): haematopoietic stem cells (95), mesenchymal stem cells 
(96) and endothelial progenitor cells (97, 98). 
Embryonic stem cells have been tested because of their strong capacity for 
expansion and subsequent differentiation into cardiomyocytes, endothelial cells 
and cardiac fibroblasts (99, 100). Induced pluripotent cells were artificially 
derived from non-pluripotent cells by specifically inducing the expression of 
genes involved in self-renewal and potency (101-103). These cells, as embryonic 
stem cells, have been tested because they have limited replication and ample 
capacity for differentiation.  
Unfortunately, these approaches had limited success as revealed by several 
studies in animal models suggesting that cellular transplantation is feasible, safe 
and beneficial, but, nonetheless, the effective regeneration of infarcted 
myocardium and cardiac function improvement are weak. Modest results have 
also been obtained due to massive cell loss, low cellular survival or lack of 
cellular effect after administration. Hypoxic conditions in the host tissue, failure 
to establish electrical or mechanical heart coupling result, in fact, in arrhythmias 
and low rates of cell differentiation into a cardiac lineage. Furthermore, the status 
of indifferentiation of embryonic stem cells generates their uncontrolled 
proliferation, giving rise to the formation of teratomas (93, 104-106), whereas 
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obtaining induced pluripotent stem cells entails the use of viral vectors that could 
also promote unwanted oncogenic activity (107, 108).  
However, the modest functional effects of transplanted stem cells stimulated 
further research into the natural regenerative mechanism of the cardiac tissue. 
 
1.3.1 CARDIAC PRIMITIVE CELLS AS STEM CELLS 
 
For several decades, the paradigm that the heart is an organ incapable of 
regenerating parenchymal cells has been questioned (15, 109-111). The belief 
that the heart is a fully differentiated organ, unable to synthesize DNA and 
undergo mitosis, has its basis on the anatomical studies of Karsner et al. (112) 
and profoundly limited investigation on myocardial regeneration potential (113). 
In the last decade, this notion has been almost completely invalidated, since 
several studies emphasized the capability of adult mammalian cardiac myocytes 
to synthesize DNA and reenter the cell cycle after a MI (114-117).  
The most interesting revolution has been the discovery in the adult heart of stem 
cells (86), that can also be isolated and explanted from human myocardium 
samples obtained using a minimally invasive biopsy procedure (118, 119). 
Stem cells and progenitor cells with the capacity to differentiate into three major 
cardiac cell types - cardiomyocytes, smooth muscle cells and endothelial cells 
have been described in both embryonic (120-122) and adult heart tissue (86, 123, 
124). The adult human heart, in particular, hosts a population of cardiac stem 
cells, positive for CD117, the stem cell factor receptor, responsible for 
physiological tissue homeostasis and, presumably, regeneration in pathological 
21 
 
conditions (111, 125-127). These cells have been characterized and the 
expression of different markers could be associated with the degree of stem cell 
differentiation. When induced to differentiate, they adopt phenotype specific for 
myocytes, smooth muscle or endothelial cells, expressing markers typical for 
these cell lineages (Nkx 2.5 and α-sarcomeric actin, GATA6, and smooth muscle 
actin, Ets-I, and FVIII, respectively). These cells are identified as cardiac 
primitive cells (CPCs), defined as cells expressing stem cell markers only, or 
together with markers of commitment towards cardiac cell lineages. Moreover, it 
was observed (46, 128-131) that the number of CD-117-positive cells in the adult 
human heart increase significantly in ischemic cardiomyopathy and pressure 
overload (46, 128, 132, 133). In addition, it has also been shown that these cells 
(as well as stem cells from other tissue) appear to reside in specialized 
microenvironment, termed niches, which support growth and maintenance of 
cells (134-135). This specific microenvironment regulates stem cell function. 
All these observations have prompted studies focusing on the regeneration of 
tissue damaged by diseases (136) or the aging process (137), as the cardiac-
resident primitive cells (CPCs) seem to be a promising target for acute and 
chronic heart disease therapy in which cardiac regeneration may be accomplished 
by enhancing the normal turnover of myocardial cells (84, 138, 139).  
 
Nevertheless, the recruitment and/or activation of these cells for cardiac repair is 
insufficient to significantly affect and prevent the deterioration in cardiac 
performance and adverse remodeling after an ischemic event. The physical 
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separation of niches from the site of injury, the formation of fibrotic scar tissue, 
or the lack of appropriate signaling are major causes of these limitations (140). In 
fact, some reports demonstrated that after myocardium infarction, new 
cardiomyocytes are produced in the border region of the infarcted area but not in 
the middle of the damaged zone (141), because dense fibrosis presents a 
formidable physical barrier to regenerating cell (142). This hostile 
microenvironment might therefore prevent the activation of resident cells and 
thus also reduce the success of exogenous cell therapies.  
Therefore, the heart is unable to regenerate, due to replacement of cells with 
fibrous tissue, which is considered central to the evolution of adverse cardiac 
remodeling, and this condition leads to progressive cardiac dysfuction. 
Nowadays, to overcome these limitations, one of the most promising approaches 
for therapeutic regeneration is cardiac tissue engineering that uses biomaterials as 
vehicles for cell delivery and retention.  
 
 CARDIAC TISSUE ENGINEERING AND BIOMATERIALS 1.4
 
Tissue engineering is an interdisciplinary scientific area that attempts to restore 
or improve the biological functions of damaged tissues or no longer able to carry 
out their function (143). This therapeutic strategy is of particular interest for the 
treatment of heart diseases, where large portions of functional tissue are lost (i.e., 
after myocardial infarction (MI)) with very limited intrinsic regeneration ability 
of the heart. In general, the tissue-engineering paradigm relies on the use of 
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combinations of cells with regenerative capacity, biomaterial scaffolds, growth 
factors, differentiation factors and proangiogenic factors (144).  
In the last decade, several strategies were developed under the concept of cardiac 
tissue engineering. One strategy uses biomaterials as vehicles for cell delivery 
and retention in the infarcted heart (145-147). The biomaterial vehicle, usually in 
the form of three-dimensional porous degradable scaffolds, providing mechanical 
support for the infarcted tissue, creates a favorable microenvironment for 
promoting transplanted cell survival and long-term action. A second strategy is 
the in vitro bioengineering of cardiac patches (144, 148) that are seeded with 
cardiac cells. The third strategy focuses on the use of biomaterials in acellular 
forms as structural restrainers and scar filling to attenuate heart remodeling and 
dysfunction (149, 150). The fourth strategy offers combination of biomaterials 
with bioactive molecules, in the form of local and controlled delivery system 
(151, 152).  
The biomaterials used in each of the strategies for myocardial repair and 
regeneration not only need to be cell and tissue compatible and biodegradable, 
with no or minimal inflammatory response after implantation, but also need to 
support cell attachment, differentiation, and proliferation (153-156). 
Biodegradable biomaterials provide a high biocompatibility due to polymer 
backbone degradation or by dissolution of the matrix, and the degradation 
products must be non-toxic and readily eliminate from the body. The biomaterial 
of the scaffolds should be porous to facilitate mass transport, hydrophilic to 
enhance cell attachment, elastic to enable transmission of contractile forces, 
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resistant to stress and strain, sterilizable and match biomechanical characteristics 
of tissue. The scaffold should be able to release growth factors, gene signals and 
other proteins (157, 158). Hence, the ideal scaffolding should mimic the 
microenvironment found within native tissue.  
 
1.4.1 BIOMATERIAL CLASSIFICATION  
 
Many different biomaterials are be used for tissue engineering, and they can be 
classified as natural and synthetic. The first group generally includes proteins and 
polysaccharides, whereas the second one is composed of metallic, ceramic or 
polymeric materials. All of them have been used to manufacture scaffolds in 
tissue engineering (159, 160).  
Natural biomaterials are usually biodegradable and biocompatible and better 
recreate the native myocardial microenvironment. The inclusion of growth 
factors and other proteins able to boost cellular functions allow their stimulating 
effects. Nevertheless, natural biomaterials can transfer pathogen associated with 
natural polymers (161).  
Synthetic biomaterials are easy to handle and can be designed with versatile 
properties, such as mechanical strength and biodegradation rate, and can be 
tailored with functional groups. However, they do not transfer pathogens (162).  
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a) NATURAL BIOMATERIALS   
 
The most popular natural biomaterials are collagen, gelatin, chitosan, alginate, 
hyaluronic acid, and fibrin. 
Collagen is the most abundant and ubiquitous structural protein in the body. It 
can be fabricated in many forms, such as hydrogel or macroporous scaffold; its 
fabrication frequently requires chemical cross-linking. Several optimal 
properties, such as being biocompatible, cell-adhesive (163), suturable, porous 
and readily combinable with other materials, have made collagen appropriate for 
use as a natural scaffold in tissue engineering applications (164-169).  
Gelatin is a natural polymer that can be obtained from bone, skin, or tendon by 
partial hydrolysis with acid or alkaline solutions. Gelatin is highly biocompatible 
and biodegradable, has low cost (170, 171) and it has been used in myocardial 
tissue engineering, especially in the format of a hydrogel prepared by chemical 
cross-linking. The gelatin under various conditions can provoke an unspecific 
inflammatory response (172). 
Chitosan is a biodegradable and biocompatible cationic polymer. Its final 
degradation products are biocompatible chitosan oligosaccharides of variable 
length (173). This natural material has the capacity to combine with conductive 
materials to improve electrical signals transmission and/or with other 
biomaterials (174, 175). Additionally, chitosan was shown to be capable of high 
growth factor retention and strong cellular receptor adhesion due to its 
hydrophilicity (176, 177).  
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Alginate is a polysaccharide extracted from brown algae and can form a hydrogel 
through ionic crosslinking with divalent cations (mainly calcium) (178, 179). 
Alginate is not degradable in mammals; yet, the calcium cross-linked hydrogel is 
readily erodible with time due to exchange of calcium ions by sodium ions in 
physiological milieu, leading to hydrogel dissolution (180). This property also 
enables incorporation and retention proteins inside the hydrogel; thus, it can be 
used as a scaffold for tissue regeneration (181, 182). Interestingly, the 
implantation of highly purified alginate, free of protein contaminants, resulted in 
a complete absence of adverse host immune response (183, 184).   
Hyaluronic acid (HA) is a linear un-sulfated polysaccharide and has versatile 
biological functions, such as a lubrificant material and numerous receptor-
mediated roles in different cell processes (185, 186). It has a bioactive role in 
several regulatory processes, such as angiogenesis, inflammation, wound healing, 
and tissue regeneration (187, 188). Hyaluronic acid acts in the ECM as space 
filler and significantly contributes to the mechanical properties of a tissue, by 
linking proteoglycans and maintaining hydration (189). 
Fibrin is a biocompatible polymer and plays an important role in injured tissue. It 
is endowed with fit properties for healing and angiogenesis (190). This polymer 
that mimics the last step of the coagulation mechanism is obtained through the 
enzymatic conversion of fibrinogen catalyzed by thrombin and followed by a 
spontaneous polymerization. Fibrinogen is a very large and long glycoprotein 
that is converted in fibrin through the action of thrombin and activated Factor 
XIIIa. This process depends largely on calcium ions and specifically consists of 
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two different stages: proteolysis of fibrinogen by thrombin, followed by the 
polymerization of fibrin monomers, and fibrin stabilization through the action of 
Factor XIIIa (191-195). When fibrin is used for engineering applications, it is 
important to understand how the formulation of the fibrin matrix affects the 
porosity, permeability, and stiffness and the subsequent effects on cells grown in 
fibrin. Several studies have shown that it is possible to control the stiffness and 
porosity by changing the concentration of fibrinogen used to make the three-
dimensional (3D) fibrin matrix. Specifically, as the concentration of fibrinogen 
increases, the stiffness of 3D fibrin matrices increases too, and the porosity 
decreases (196-198). These findings are significant as porosity is important for 
nutrition uptake, gas exchange and waste removal. Fibrin scaffolds were 
prepared as hydrogels and in injectable forms, where its components (fibrinogen 
and thrombin) are mixed during injection into the tissue. 
Fibrin is an excellent scaffold for tissue engineering because it has several 
advantages such as its components that can be autologously harvested and its 
degradation products are physiological and therefore nontoxic (199); they are not 
allergenic or inflammatory (200). Then, fibrin has the potential to incorporate 
both cells and cell mediators (heparin and/or growth factors), with the potential 
to replicate a specific microenvironment. Moreover, the fibrin network has a 
nanometric fibrous structure, with a high area/volume ratio, mimicking ECM 
(201). In fact, it provides a suitable matrix for cell growth, differentiation and 
function (202), and for these reasons, fibrin is also used for the construction of 
cellularized scaffolds or “patches” that are placed over the infarcted myocardium 
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to provide optimal cell retention and implantation at the sites of injury (203). In 
particular, the presence of arginine-glycine-aspartic acid motifs within the fibrin 
network allows cell adhesion and binding of growth factors (204). The high 
elasticity of fibrin gel in comparison to other characterized protein gels is another 
essential aspect for its efficiency as a cell matrix (190), because its fibers are 
extraordinarily extensible and elastic. Fibrin has also viscous properties that can 
vary greatly, depending on clot structure and biochemical properties (205).  
Hence, fibrin scaffolds are good candidates for treating MI due to their high 
biocompatibility, biodegradability and capacity of incorporating different cell 
types. In addition, fibrin scaffolds can be assembled with other scaffolds 
materials (206-208). Due to its intrinsic properties, application of fibrin patch 
alone (without cells), in combination with other materials, or with cardiac ECM, 
have provided acceptable cell viability, and its administration was been feasible 
(209-211). 
In fact, fibrin gels have been successfully used in cardiovascular system, as cell 
and growth factor delivery vehicles to reduce ischemia and improving their 
survival within ischemic tissues (212), representing a good and plausible 
possibility for regenerating infarcted myocardium. 
 
b) SYNTHETIC BIOMATERIALS  
 
Synthetic materials are widely used in myocardial tissue regeneration, due to 
some excellent characteristics. First of all, they generally show superior 
mechanical properties than natural polymers that make them suitable for 
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mechanical support and resistance to cyclic stress of force-generating contractile 
tissue (153, 213). In addition, these properties, together with hydrophilicity and 
degradability, can be controlled in a reproducible manner. Their drawbacks 
regard the poor interaction with cells and the biological environment  and their 
capacity to induce higher inflammatory reaction (213).  
The most popular synthetic biomaterials employed in cardiac tissue regeneration 
are degradable polyesters. Although their biocompatibility has been proved and 
several reports on their successful applications in regenerative medicine exist, 
synthetic polymers have not yet considered optimal scaffolding materials. They 
are basically hydrophobic, preventing a good cell adhesion, and tend to crumble 
rather than slowly degrade. In addition, their acid biodegradation products can 
induce high inflammatory responses, and a drop in local pH, upon degradation 
process, can affect the viability of the surrounding cells (213). Synthetic 
polyesters such as poly lactic acid (PLA), poly glycolic acid (PGA) (214), poly 
caprolactone (PCL) (215), and poly lactic-co glycolic acid (PLGA) have 
generated immense interest as tissue engineering materials.  
 
PGA is a rigid thermoplastic material with high crystallinity and hydrophilicity; it 
has a simpler structure than PLA, but PLA is more hydrophobic and less 
crystallizable and, for this reason, it degrades slower than PGA. However, PLA 
dissolves easier in organic solvents (216). From the combination of glycolic acid 
and lactic acid, copolymers poly lactic-co-glycolic acid (PLGA) have been 
obtained. Like PGA and PLA, PLGA they have a long history in clinical 
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applications (217, 218). These materials provide rigid structures of medium 
mechanical strength, in which cells adhere and grow on a pseudo three-
dimensional environment (219). 
PCL, which is a non-toxic compound, is known to be compatible and to have a 
long-term degradability, if compared to PLA, PGA, and PLGA.  From 
mechanical point of view, PCL seems to be the less stiff polyester with a 
remarkable high strain at failure (220).   
These polymers have been mainly used as solid macroporus scaffold for cardiac 
patch reconstruction. 
In addition to polyesters, polyurethanes (PURs), other extensively explored 
materials, are a large group of polymers that have been studied for a long time, 
because of their biocompatibility (221, 222) and elastomeric properties 
(capability to resist to cyclic stress without plastic deformation or failure) that fit 
the requirements of materials for cardiovascular applications (223).  
Although synthetic materials seem to be promising, they lack some properties, as 
they provide a poor interaction with cells, therefore, the challenge is to find the 
“perfect” biomaterial with the proper three-dimensional structure and the 
appropriate environment for retention of stem cells after implantation.  
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 BASIC SCAFFOLD FABBRICATION FORMS: HYDROGELS 1.5
 
Hydrogel is a network of polymer chains that are water-insoluble, sometimes 
found as a colloidal gel in which water is the dispersion medium. Hydrogels are 
superabsorbent (they can contain over 99% water) natural or synthetic polymers. 
Hydrogels also possess a degree of flexibility very similar to natural ECM, due to 
their significant water content. The hydrogels can be prepared from natural and 
synthetic polymers by physical/ionic interactions (alginate) or via chemical 
cross-linking (collagen, HA, and others). Cells are incorporated/encapsulated in 
the hydrogel during fabrication.  Due to their resemblance to ECM texture, 
hydrogels are extensively being investigated as ECM replacements for damaged 
ECM after MI. They are delivered either by intramyocardial injection or by 
catheter-based techniques via the intracoronary route (209). 
 
 ACELLULAR BIOMATERIALS FOR CARDIAC REPAIR  1.6
 
In parallel to the development of 3D matrices prepared from biological or 
synthetic materials, the emerging direction is the use of natural ECM as an 
appropriate matrix for cardiac tissue engineering through the process of organs 
and/or tissues decellularization.  
The goal of tissue decellularization is to efficiently remove cells and cell 
remnants while retaining the three-dimensional ultrastructure and composition of 
the native ECM to the extent possible (224). Residual cellular material within 
ECM may contribute to cytocompatibility problems, in vitro, and adverse host 
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responses, in vivo, upon reintroduction of cells (225-228). Through the removal 
of cellular antigens, the matrix could be used without inducing a foreign body 
reaction, inflammation, and potential transplant rejection (229) and would be 
considered biocompatible. Although complete removal of all cell remnants is not 
possible, analyses suggested that the decellularization could be considered 
acceptable when the amount of DNA is less than 50 ng per mg of dry tissue of 
ECM, the remaining DNA fragments have a length less than 200 bp, and when 
there is no visible nuclear material in tissue sections stained with 4’,6-diamidino-
2-phenylindole DAPI or hematoxylin and eosin (H/E) (230).   
Moreover, degradation products of decellularized matrix have angiogenic (231) 
and chemoattractive properties and promote cell migration and proliferation 
(231-234). 
Therefore, about the importance of ECM, preservation of this complex structure 
is pivotal in the decellularization process (235, 236). 
Several techniques for decellularization have been developed, depending on 
characteristics of each tissue, including its cellularity, density, lipid content, and 
thickness. Several physical, chemical or enzymatic treatments have been tested. 
Examples of physical methods are: freeze-thaw cycles that produce minor 
disruptions in the tissue ultrastructure (224) and electroporation that induces the 
formation of micropores that cause loss of cell homeostasis and leads to cell 
death (237). 
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There are also various chemical treatments to achieve an ideal decellularization: 
acids and bases, that cause or catalyze hydrolytic degradation of biomolecules; 
hypotonic and hypertonic solutions, that cause cell lysis and dissociate DNA 
from proteins, respectively (238); alcohols such as isopropanol, ethanol, and 
methanol are more effective than lipase in removing lipids from tissues, but 
damage ECM and they can precipitate proteins; detergents that solubilize cell 
membranes and dissociate DNA from proteins, and they are therefore effective in 
removing cellular material from tissues (triton X-100, sodium deoxycholate, 
sodium dodecylsulfate, 3-[(3-cholamidopropyl) dimethyl ammonio]-1-
propanesulfonate (CHAPS)) (238). Triton X-100 can effectively remove cell 
residues from thicker tissues (239), but sodium dodecyl sulfate (SDS) appears 
more effective than Triton X-100 for removing nuclei from dense tissues and 
organs (230) and its addition to a decellularization protocol can make the 
difference between complete and incomplete cell nuclei removal (240).  
Biological agents are also common: enzymes that include nucleases, trypsin, 
collagenase, lipase, dispase, thermolysin, and α-galactosidase can provide high 
specificity for removal of cell residues or undesirable ECM constituents. 
However, complete cell removal by enzymatic treatment alone is difficult and 
enzyme residues may impair recellularization or evoke an adverse immune 
response (241); chelating agents as ethylenediaminetetraacetic acid (EDTA) and 
ethylene glycol tetraacetic acid (EGTA) induce cell dissociation from ECM 
proteins by sequestering metal ions (242), but they can contribute to disruption in 
protein-protein interactions by the same mechanism (243).  
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To date, many organs and tissues have been completely decellularized, including 
heart valves, myocardium, pericardium, lung, pancreas, kidney, liver, mammary 
gland, and nerve (241, 244). Ideally, the best source of a decellularized matrix for 
myocardial repair should be the matrix derived from the myocardium, which 
potentially possesses the composition and structure required for the specific 
needs of reconstructing the heart (245). The use of decellularized matrices from 
natural ECM sources represents an attractive approach, as in this way the 
properties of the resulting scaffold may potentially be matched to the target 
tissue, including the heart. However, several technical issues are still to be 
solved, such as the need for effective decellularization protocols, possible 
immunogenicity, preservation/ storage. 
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2. HYPOTHESIS AND AIM OF THE STUDY 
 
Microenvironment can strongly influence survival, differentiation, and control 
biological activity of stem cells and their progeny. Hence, for a successful 
transplantation, a suitable microenvironment into which CPCs can survive and 
differentiate is required. 
The ECM obtained from the decellularized cardiac tissue is a promising construct 
and it can be utilized to repair damaged areas of myocardium by promoting its 
vascularization and cardiac stem cells proliferation and differentiation. It 
potentially possesses the composition and the architecture required for 
reconstructing the heart, but solubilizing ECM and reforming it into a hydrogel, 
gels have a limited range of mechanical properties that do not match the native 
myocardium, thus pure ECM hydrogels cannot be used as a three-dimensional 
scaffold for cells.  
Since biomaterials can improve cell retention, survival and differentiation, they 
are widely used in cardiac tissue engineering, to support cell-based therapies and 
enhance their efficacy for cardiac diseases. 
Many biocompatible biomaterials have been used and among the ones tested, 
fibrin is an ideal candidate. 
Fibrin is a versatile, FDA-approved material, known to form hydrogels with 
tunable mechanical properties. Fibrin gels have many positive characteristics that 
qualify them as good scaffolds for tissue engineering. However, fibrin itself does 
not entirely mimic the complex microenvironment of the heart. 
36 
 
Therefore, the overall goal of this study was to develop cardiac hybrid-scaffold, 
by combining cardiac decellularized ECM with fibrin, to assess if the construct 
obtained could be used as a three-dimensional scaffold for CPCs, and if it was 
able to improve cell culture quality, in vitro, and to treat myocardial infarction in 
vivo. 
More specific aims were: 
 To isolate and characterize CPCs from pathological adult human hearts; 
 To develop a novel and specific protocol of decellularization to obtain 
cardiac ECM; 
 To characterize the resulting cardiac d-ECM;  
 To solubilize cardiac d-ECM and incorporate it into fibrin gels made with 
different fibrin/ matrix ratios;  
 To establish which ratio could better mimic the extracellular 
microenvironment; 
 To characterize hybrid scaffold by histological analysis. 
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3. MATERIALS AND METHODS 
 
 CARDIAC TISSUE SAMPLES 3.1
 
Cardiac tissue samples were obtained from pathological adult human hearts of 
patients undergoing heart transplantation because of end-stage heart failure due 
to ischemic cardiomyopathy (n = 20, 14 males and 6 females, mean age 56 ± 5.5 
years, mean ejection fraction 25 ± 1%). Samples were harvested from 
macroscopically uninjured areas of the free wall of the left ventricle of explanted 
hearts. Specimens were collected, without patient identifiers, following protocols 
approved by the Monaldi Hospital and in conformity with the principles outlined 
in the Declaration of Helsinki.  
 
  CELL CULTURES  3.2
3.2.1 ISOLATION OF CARDIAC PRIMITIVE CELLS  
 
Cardiac tissue samples, isolated from pathological adult human hearts, were 
dissected, minced, and enzymatically disaggregated by incubation in 0.25% 
trypsin for 6 hours at 4°C and 0.1% (w/v) collagenase II (both from Sigma-
Aldrich, St. Louis, MO, USA) for 30 minutes at 37°C. The digestion was stopped 
by adding a double volume of Hank’s Balanced Salt Solution (HBSS) 
supplemented with 10% fetal bovine serum (FBS) (both from Sigma-Aldrich). 
This preparation was further disaggregated by pipetting and tissue debris and 
cardiomyocytes were removed by sequential centrifugation at 100g for 2 
minutes, passage through 40 𝜇m cell strainer (BD Biosciences, Franklin Lakes, 
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NJ, USA), and centrifugation at 400g for 5 minutes. Cell population was seeded 
on culture dishes in Nutrient Mixture F-12 Ham (F12K) (Sigma-Aldrich) 
supplemented with 10% FBS, 5% horse serum, 0.2 mM glutathione, 5U/L 
erythropoietin, 50 µg/ml porcine gelatine, 10 000 U penicillin and 10 mg/ml 
streptomycin (all from Sigma-Aldrich) and 10 ng/ml basic fibroblast growth 
factor (Peprotech, Rocky Hill, NJ, USA). The cell population was cultured for a 
time ranging from one to 2 weeks. Once the adherent cells were more than 75% 
confluent, they were detached with 0.25% trypsin-EDTA (Sigma-Aldrich) and 
the cell suspension was used to isolate cardiac primitive cells (CPCs) by 
immunomagnetic cell sorting. In particular, cell suspension, previously depleted 
of fibroblasts, was incubated with anti-human-CD117 MicroBeads (Miltenyi 
Biotec, Bergisch Gladbach, Germany) and passage through columns placed in 
magnetic field, to purify the positive fraction of CD117-positive cardiac 
primitive cells (CPCs).  
 
3.2.2 CULTURE OF CARDIAC PRIMITIVE CELLS  
 
CD117-positive CPCs were plated at a density of 4x10
3
cells/cm
2
 in F12K 
medium (Sigma-Aldrich) supplemented as reported above. In order to check the 
effectiveness of sorting, CPCs were fixed in 4% paraformaldehyde for 20 min at 
room temperature and incubated with 10% donkey serum to block unspecific 
binding of secondary antibodies. Cells were incubated with primary antibody 
against the human stem cell marker CD117 (mouse monoclonal, Merck 
Millipore, Billerica, Massachusetts, USA), followed by an incubation with 
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secondary antibodies conjugated with rhodamine (Jackson ImmunoResearch 
Europe, Newmarket, UK). Nuclei were counterstained with DAPI (Merck 
Millipore). Stained area of culture dish was mounted in Vectashield (Vector 
Labs, Burlingame, CA, USA). Microscopic analysis was performed with a Leica 
DMLB microscope equipped with epifluorescence EL6000 system (Leica 
Microsystems, Wetzlar, Germany) and connected to a digital camera DFC345FX 
(Leica Microsystems).  
CD117-positive CPCs at passage 5 were then used to assemble fibrin gels. 
 
 CARDIAC TISSUE SECTIONING 3.3
 
Samples of left ventricle from explanted hearts were harvested, snap-frozen and 
stored at -80°C until use. Specimens were mounted on a cryostat (Leica 
Microsystems) chuck using filling medium (Bio-Optica, Milan, Italy) and sliced 
into 350-µm-thick sections. Sections obtained were used either for the 
decellularization or as control for molecular analysis. Three sections  were fixed 
in formalin for paraffin embedding and histochemical analysis. 
 
 DECELLULARIZATION OF CARDIAC TISSUE 3.4
 
Cardiac tissue sections were decellularized using a combination of sodium 
dodecyl sulfate (SDS) and Triton X-100. Specifically, sections were 
decellularized in a 1% SDS and 1% Triton X-100 solution (both from Sigma-
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Aldrich) in distilled water, for 24 hours. Cardiac decellularized ECM (d-ECM) 
was then transferred in PBS containing 100 U/ml of Penicillin, 50U/ml of 
Streptomycin and 0.25 μg/ml Amphotericin B (all from Sigma-Aldrich) for 24h, 
followed by wash in distilled water for 30 minutes. All processing steps were 
performed under constant mild agitation and at room temperature. Cardiac d-
ECM was stored at 4° C in F12K medium until use. Additionally, three sections 
were fixed in formalin for paraffin embedding and histochemical analysis, while 
all other sections were stored at -80° C until their use for molecular analysis.  
 
 CHARACTERIZATION OF d-ECM  3.5
 
3.5.1 QUANTITATIVE MEASUREMENT OF DNA CONTENT 
 
To assess the complete removal of cellular nucleic component after 
decellularization process, genomic DNA (gDNA) was extracted from frozen 
native (not decellularized) and decellularized cryosections, using All Prep 
DNA/RNA Mini kit (Qiagen, Hilden, Germany), following manufacturer’s 
instructions.  
Briefly, tissue samples were lysed and homogenized in a highly denaturing 
buffer containing guanidine-isothiocyanate, which immediately inactivates 
DNases, to ensure isolation of intact DNA. Lysates were then passed through an 
AllPrep DNA spin column, which, in combination with the high-salt buffer, 
allows selective and efficient binding of gDNA. The columns were washed and 
pure, ready-to-use, then DNA was eluted. 
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DNA concentration was quantified by measuring the absorbance at 260 nm using 
Nanodrop 1000 (Thermo Scientific, Waltham, MA, USA) and the gDNA band 
was visualized by electrophoresis in 0,8% agarose gel and photographed under 
UV-light exposure with FireReader XS D-55 imaging system equipped with 1D 
software (UVItec Limited, Cambridge, UK). Data were averaged and expressed 
as mean values ± SD of ng of DNA/mg of dry tissue. 
 
3.5.2 HISTOLOGICAL ANALYSIS  
 
Native and decellularized sections were fixed in 10% (v/v) neutral buffered 
formalin for 24 h, dehydrated in graded ethanol series, cleared in xylene, 
infiltrated and embedded in paraffin. Sections were sliced into 6.0 µm, mounted 
on poly-lysine-coated glass slides, deparaffinized, rehydrated and stained for 
Hematoxylin and Eosin (H&E), Sirius Red, Masson’s Trichrome, and 
paraldehyde fuchsin Gomori, using specific staining Kits (all from Bio-Optica, 
Milan, Italy). H&E staining was used to evaluate the effectiveness of 
decellularization procedure. Masson’s staining was used to evaluate the 
architecture of d-ECM, while Sirius Red and Gomori stain kits were employed to 
detect collagen and elastic fibers respectively in d-ECM sections. The 
microscopic analysis was performed by using a light microscope Leica 
DM2000LED (Leica Microsystems, Wetzlar, Germany ) connected to the digital 
camera Leica ICC50 HD (Leica Microsystems), for microscopic 
photodocumentation. 
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 LYOPHILIZATION AND SOLUBILIZATION OF d-ECM  3.6
 
Cardiac d-ECM, frozen at -80°C, was lyophilized overnight and became a milled 
powder. Then the lyophilized matrix underwent to enzymatic digestion by 0.5 
mg/ml Pepsin (Sigma-Aldrich) dissolved in 0.1 M hydrochloric acid (HCl). A 
20:1 ratio of d-ECM:Pepsin was digested on tube rotator at 37°C. After 24 hours, 
when completely solubilized, as indicated by the lack of particles in solution, d-
ECM was neutralized to a pH 7.4, at room temperature, through the addition of 
1M sodium hydroxide (NaOH) (Sigma-Aldrich), in order to cease pepsin 
activity. The solution containing cardiac d-ECM was used in combination with 
CPCs to assemble fibrin gels. 
 
 PREPARATION OF ECM-FIBRIN HYBRID-SCAFFOLDS  3.7
 
3.7.1 PREPARATION OF COMMERCIAL INJECTABLE FIBRIN 
SEALANT  
 
Modified and optimized, for these experiments, according manufacture’s 
protocol, commercial injectable TISSEEL fibrin sealant (Baxter, Los Angeles, 
CA, USA) was prepared, to create 3D scaffolds incorporating 20 mg/ml of 
cardiac d-ECM, obtained as described in section 3.6. TISSEEL consists of 2 
components, one containing fibrinogen, factor XIII and aprotinin, and one 
containing a mixture of thrombin and calcium chloride (CaCl2). The two 
components were taken, in sterile conditions, from a double-chamber syringe, 
and then gently sequentially mixed with d-ECM solution in each well of 8-well 
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glass chamber slides (Nunc, Thermo Scientific). Five different ratios of fibrin to 
matrix (F:M) were tested (1:1, 2:1, 3:1, 4:1, and 1:4) to obtain a well-structured 
scaffold with the highest possible content of d-ECM.  
 
3.7.1.1 CHARACTERIZATION OF COMMERCIAL INJECTABLE 
FIBRIN SEALANT 
 
To evaluate the histological structure of the ECM-fibrin hybrid-scaffolds, gels 
were fixed in 10% neutral-buffered formalin for paraffin embedding and sliced 
into serial 6 µm thick sections, as previously described in section 3.5.2. Then the 
sections were stained using Sirius Red, Mallory's Trichrome and PAS staining 
kits (all from Bio-Optica), according to the manufacturer’s protocol. 
Sirius Red and Mallory’s Trichrome stainings were used to detect the presence of 
collagen within the gels, while Pas stain was employed to detect glycogen, and 
mucosubstances such as glycoproteins, glycolipids and mucins within the gels. 
Microscope observation was performed by using a light microscope Leica 
DM2000LED (Leica Microsystems) connected to a Leica ICC50 HD digital 
camera connected to the microscope (Leica Microsystems). 
 
3.7.2 PREPARATION OF FIBRIN GEL BY SINGLE COMPONENTS: 
FIBRONOGEN AND THROMBIN  
 
Additionally, in order to obtain 3-D scaffolds of fibrin, cardiac d-ECM and 
CPCs, gels were prepared, using as a reference the TISSEEL but modifying the 
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concentration of each single component. In particular 100 mg/ml bovine 
fibrinogen, 40 IU thrombin from bovine (both from Sigma-Aldrich), cardiac d-
ECM at final concentration of 20 mg/ml and 3x10
6
 CPCs were combined. The 
fibrinogen was first reconstituted in a solution containing 30012 KIU/ml of 
bovine aprotinin (Sigma-Aldrich) and then was prewarmed in a 37°C water bath 
for 45-90 minutes to allow the complete dissolution. Also thrombin was first 
reconstituted in 40µM of calcium chloride solution (CaCl2) and then was warmed 
at 37°C. Briefly, reconstituted fibrinogen solution was added into each well of 8-
well glass chamber slides (Nunc, Thermo Scientific) and sequentially mixed with 
the d-ECM, previously dissolved in pepsin solution as described in section 3.6. 
Successively, cell suspension (CPCs) and at the end thrombin solution were 
added and mixed into each well (final volume: 340 µl/well). In order to favor an 
homogenous distribution of cells and components of fibrin within the gels, all 
components were gently pipetted, and then the so obtained d-ECM-CPC fibrin 
gels were left to polymerize in incubator at 37°C in 5% CO2 for 8 h, before 
carrying out further experiments. The d-ECM fibrin gels were assembled with 
low ratios of F:M, precisely 1:1, 1:2 and 2:1.  
After gelling, F12K medium (Sigma-Aldrich) supplemented as reported above, 
was added to each well, and constructs with incorporated cells were maintained 
in culture for 72 hours. During this period, the morphology of cells was evaluated 
by an inverted phase contrast microscope with Nikon Eclipse Ti-E DS-Qi2 
Microscope (Nikon Instruments Europe, Holland). 
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3.7.2.1 CHARACTERIZATION OF FIBRIN GEL BY SINGLE 
COMPONENTS: FIBRONOGEN AND THROMBIN 
 
After 72 hours, gels were fixed in 10% neutral-buffered formalin for paraffin 
embedding and sliced into serial 6 µm thick sections, as previously described in 
section 3.5.2. Serial sections of gels were stained with Hematoxylin and Eosin, 
Masson’s Trichrome, Sirius Red and PAS Morel-Maronger modified stains using 
specific kits (all from Bio-Optica) and following manufacturer's protocol. 
Hematoxylin and Eosin stain served to determine the presence and the 
distribution of cellular component in the gels, while Masson’s Trichrome and 
Sirius Red stain kits were employed to detect collagen in the gels. Finally, PAS 
stain kit was used to detect glycogen and mucosubstances, such as glycoproteins, 
glycolipids and mucins in the gels. Sections stained were then observed using a 
light microscope Leica DM2000Led (Leica Microsystems) equipped with the 
digital camera ICC50 HD (Leica Microsystems). 
 
  STATISTICAL ANALYSIS 3.8
 
Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad 
Software, La Jolla, Ca, USA). All data were expressed as the mean ± SD. A 
value of p<0.05 was used to identify any statistically significant differences.  
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4. RESULTS 
 
 CELL CULTURES  4.1
 
The observation by phase contrast microscope provided image of primary cell 
culture obtained from pathological adult human hearts as shown in Fig. 1.  
 
4.1.1 CHARACTERIZATION OF CARDIAC PRIMITIVE CELLS 
 
CD117-positive cells isolated from pathological adult human hearts and sorted, 
as described in Materials and Methods (section 3.2.1), were stained by 
immunofluorescence to confirm the purity of cell population, which resulted 
equal to 98%, as shown in Fig. 2.  
Phase contrast microscope image shows sorted population of CPC-P (Fig. 3).  
 
 DECELLULARIZATION OF CARDIAC TISSUE 4.2
 
Thick sections of native cardiac tissue of 350 µm are shown in Fig. 4 A. 
After 24 h of decellularizing treatment (Table 1) with SDS (1%) and Triton-
X100 (1%), macroscopic observation of cardiac tissue sections showed the 
typical color change from brown to translucid-white occurring during the 
process, as a result of a complete and effective decellularization procedure (Fig. 
4 B) 
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4.2.1 CHARACTERIZATION OF d-ECM 
 
4.2.1.1 QUANTITATIVE MEASUREMENT OF DNA CONTENT 
 
To test the effectiveness of decellularization procedure, quantitative 
measurement of DNA content was performed both in decellularized and native 
cryosections. This analysis confirmed the presence of a lower amount of DNA 
content in decellularized sections (d-ECM) (3.5 ± 0.71 ng/mg dry tissue) 
compared with native sections (116, 2 ± 1,13 ng/mg dry tissue), as shown in Fig. 
5 A.  
To assess the quality of DNA extracted, electrophoresis was performed on 0.8% 
agarose gel. No DNA band was visualized for decellularized samples, while the 
band for native samples was clearly visible (Fig. 5 B) 
 
4.2.1.2 HISTOLOGICAL ANALYSIS  
 
The histological analysis confirmed the effectiveness of the decellularization 
procedure, in fact Hematoxylin and Eosin staining showed no evidence of whole 
cell or fragments in the decellularized sections when compared to native sections, 
which present nuclei and cellular components. Moreover, Sirius Red and Gomori 
stainings documented the retention, in d-ECM, of collagen, and the presence of 
elastic fibers, respectively; while Masson’s Trichrome staining revealed a well 
preserved three-dimensional architecture of d-ECM (Fig. 6). 
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 LYOPHILIZATION AND SOLUBILIZATION OF d-ECM 4.3
 
d-ECM, as shown in Fig. 7, was lyophilized, milled into a powder, and finally 
solubilized with a pepsin digestion. The pepsin concentration (0.5 mg/ml), the 
temperature (37°C) and the turning on tube rotator were all the conditions 
suitable to digest d-ECM; in fact, after approximately 24 h, d-ECM appeared 
completely solubilized as indicated by the lack of ECM particles in solution. 
Solution of d-ECM remained a viscous liquid on ice or at room temperature. 
 
 CHARACTERIZATION OF COMMERCIAL INJECTABLE 4.4
FIBRIN SEALANT 
 
It was attempted to make scaffolds composed solely of commercial injectable 
fibrin sealant and cardiac d-ECM. Five different ratios of F:M (1:1, 2:1, 3:1, 4:1, 
and 1:4) were tested, and it was found that fibrin sealant gelled within few 
seconds, and pipetting was tricky, thus resulting in an uneven incorporation of d-
ECM in the gel. Furthermore, it was observed that when F:M ratio was too high 
(3:1; 4:1), the polymerization of fibrin was too rapid and the gels became stuck 
inside the micropipette tips during the mixing of d-ECM.  In addition, Mallory’s 
Trichrome and Sirius Red stainings revealed that collagen distribution and 
orientation were not homogenous, especially when F:M ratio was too high (3:1; 
4:1). Also PAS staining revealed that the presence of glycoproteins in the gels 
appeared not consistent and uniform (Fig. 8). With F:M ratio at 1:4, the fibrin 
appeared loosely compacted, resulting slightly viscous and was fragmented after 
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detachment from each well and hence not properly gelling. With this ratio, it is 
not possible to visualize a proper distribution of the matrix, as shown in Fig. 8. 
 
 CHARACTERIZATION OF FIBRIN GEL BY SINGLE 4.5
COMPONENTS: FIBRINOGEN AND THROMBIN  
 
4.5.1 QUALITATIVE ANALYSIS 
 
To prevent fast gelling, gels were prepared starting from single components of 
fibrin. In particular, three F:M ratios (1:1, 1:2 and 2:1) were tested to select those 
that met the incorporation into fibrin gels of d-ECM and CPCs.  
Using F:M ratio of 1:2, the higher quantity of d-ECM inhibited a proper 
polymerization of fibrin, consequently fibrin gels were difficult to manipulate, 
very small, and they were fragmented after detachment from each well.   
Whereas, with F:M at ratio of 2:1, d-ECM was not packed among fibrin’s 
components. The higher quantity of fibrin, in fact, inhibited the homogenous 
incorporation of d-ECM in the gel: the gels were easier to handle, densely packed 
on the bottom of the well, with a small quantity of aqueous solution on the 
surface, and they resulted not fragmented after detachment from each well. 
Gelling time, in both ratios, varied from one to twenty hours. 
With F:M at ratio of 1:1, gels gelled after 8 hours, they were easier to handle and 
densely packed. In addition, macroscopic observation of gels after 8h showed the 
typical uniform white color, as a result of a perfect gelling. They resulted not 
fragmented after incubation, and they were easily to manipulate.  
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4.5.2 HISTOLOGICAL ANALYSIS  
 
Histochemical stainings revealed the presence of CPCs in the gels whose 
architecture varied from densely packed (F:M 2:1), very loose (F:M 1:2), to 
proper packed (F:M 1:1). 
Related to the ratio of fibrin to matrix, homogeneous distribution of cells is 
showed by H&E only in the gels with F:M ratio of 1:1. With F:M ratios of 2:1 
and 1:2, the cell distribution is visible around the perimeter of each gel as shown 
in Fig. 9.  
Masson’s trichrome staining indicated that collagen fibers were present in the 
gels with F:M ratio of 1:1 and they appear blue when compared to the ratios F:M 
ratios of 2:1 and 1:2, where d-ECM were not very visualized (Fig. 9) 
PAS and Sirius Red stainings have shown the presence of glyproteins and 
collagen, respectively, in the gels with F:M ratio of 1:1, when compared to the 
ratio F:M ratios of 2:1 and 1:2 (Fig. 9) 
Phase contrast microscope pictures showed CPCs embedded in fibrin gels at 
different F:M ratios ( 1:1, 1:2, and 2:1) (Fig. 10).  
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5. DISCUSSION AND CONCLUSIONS 
 
Cardiovascular diseases are the leading cause of death worldwide and one of 
their most important clinical manifestations is represented by MI (4), which 
results in the irreversible loss of cardiomyocytes accompanied by scar formation, 
progressive alteration in the geometry of heart, ventricular remodeling and a 
pathologically modified extracellular matrix (82). Currently, the only successful 
treatment for end-stage heart failure post-MI is the total heart transplantation. 
Nonetheless, transplantation is highly limited by heart donor availability and host 
immunological response against the donated organ (82).  
As a result, there is great interest in alternative therapeutic strategies to reverse 
this common and deadly disease. One of these strategies accounts the concept of 
increasing the number of contractile cells through the transplantation of viable 
cells, in the infarcted zone, that function as normal cardiac cells and integrate 
into the host tissue so that heart function can be restored.  
In these circumstances, stem cell-based therapeutic option, generating new 
cardiomyocytes, has emerged as a promising treatment for both myocardial 
infarction and heart failure. Several cell types that might replace necrotic tissue 
and minimize scarring have been considered; among multiple stem cells tested, 
cardiac primitive cells (CPCs) have the most promising therapeutic potential 
(246). They can be isolated from normal and pathological human hearts, and as 
stem cells, CPCs are self-renewing, clonogenic, multipotent, and able to 
differentiate into the three cardiovascular lineages of the heart: endothelial cells, 
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vascular smooth muscle cells and cardiomyocytes (86, 120-124), arousing an 
increased interest about myocardium regenerative processes.  
Despite encouraging results in stem cell-based therapy, the lack of an appropriate 
extracellular environment for cellular adhesion has limited cell retention, 
survival, and integration into the host tissue within the damaged infarct region 
(247-249).  
All the cells, in fact, exist in vivo in a specialized environment in which their 
survival and function is assured, while their biological activity is controlled. This 
environment, mainly formed by the extracellular matrix (ECM) and supporting 
survival, proliferation, and differentiation of resident cell populations, provides 
the perfect, unique environment for every organ cell (250-251). Moreover, this 
environment has mechanical properties that can play a critical role in directing 
cell response (252-253). 
Since, during a cardiac disease, including myocardial ischemia, qualitative and 
quantitative alterations in ECM proteins are ensured (254), it seems reasonable 
that the role of extracellular matrix and the effects of the modifications of its 
composition ongoing in pathological conditions could be associated with poor 
cell engraftment, survival, differentiation and retention in the infarct area. Hence, 
considering the influence of the microenvironment on cells, it is essential to 
restore the extracellular compartment along with the cellular compartment. 
More recently, biomaterials with their own intrinsic biological activity, have 
offered a plausible solution to the drawbacks encountered previously. They are 
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desirable as delivery vehicles to help improve cell retention and to contribute to 
replace lost tissue and re-establish damaged connections after MI. Both synthetic 
and natural biomaterials have been investigated for use in cardiac tissue 
engineering applications. Many of these biomaterials have been used to form 
implantable scaffolds incorporating cells and mimicking an ECM-like structure 
(222). However, immune rejection, degradation, and mechanical integration 
problems have limited the success of many biomaterials in cardiac repair (222, 
255), moreover the implantation of these scaffolds involves an invasive 
procedure.  
Based on these premises, this work aimed to construct an injectable scaffold as 
potential cell deliver directly into the infarcted area replacing the damaged 
myocardial ECM, and, at the same time, offering a minimally invasive delivery 
approach. 
Currently, d-ECM in cardiac regenerative medicine offered a neat solution to 
synthetic material issues. It enhances cellular functions, such as survival, 
maturation, differentiation and migration (256), in addition it possesses the 
composition and architecture required for reconstructing the heart, and its 
degradation products have been shown to be chemo-attractive (235, 257).  
Thus, solubilizing d-ECM and reforming it into a hydrogel could be a promising 
method to develop an injectable material (258) capable of restoring the integrity 
of the myocardium. Unfortunately, ECM hydrogels have a limited range of 
mechanical properties that do not match the native myocardium, consequently, 
pure ECM hydrogels cannot be used for 3-D cell encapsulation (259-261).  
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To solve this problem, the final aim of this study was to develop a natural 
injectable self-assembling scaffold able to serve as both three-dimensional 
platform and cell delivery method, by combining two substrates:  
 ECM from ex vivo decellularized heart tissue, which mimics the 
complex properties of the cardiac microenvironment;  
 fibrin, which possesses tunable mechanical properties and elasticity of 
the native myocardium, that distinguish it from all other biomaterials 
(262, 263). Moreover, fibrin can be modified to incorporate biologically 
active peptides which facilitate cell adhesion, improve cell-cell 
interaction, support cell migration and differentiation inside the gel 
(161).  
Based on these considerations, the first step of the work was to decellularize left 
ventricle of pathological human heart in order to obtain a cardiac ECM that could 
be tuned to mimic the native and ideal cardiac environment for CPCs. 
A major limitation of decellularized materials is their immunogenicity and the 
risk of diseases transfer when derived from xenogeneic or allogeneic sources. 
Conversely, using the patient’s own tissue to produce a tissue engineered 
scaffold could avoid or reduce similar endogenous consequences (264).  
The ultimate goal of the tissue engineering is to design and fabricate natural-like 
functional human tissues suitable for regeneration, repair and replacement of 
damaged, injured or lost human organs (265-268). An ideal human engineered 
tissue must eliminate, dramatically reduce, or more realistically reinvent the 
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problem of biocompatibility (225-228) which is a critically important issue for 
any biomaterial-based approach. 
The cardiac ECM comprises complex and specific mixture of proteins, and this 
composition changes throughout heart development and maturation (269). The 
ECM was, hence, obtained decellularizing pathological human ventricle samples 
by a previously developed and tested procedure (270). The protocol allowed to 
produce a d-ECM perfectly suited for the scope, as it was acellular, with a weak 
residual content of DNA that made it almost completely non immunogenic, 
limiting the eventual inflammatory response of the host (271). Furthermore the 
architecture was preserved and an optimal retention of structural ECM proteins 
occurred. Supporting the fact, H&E images has revealed empty spaces in 
diameter where cells may have been located prior to the decellularization 
procedure. Finally, d-ECM obtained showed a good preservation of collagen and 
elastic fibers, which are well known as critical elements for the structural 
integrity and biomechanical profile of tissue engineered constructs (272): the 
collagen network is a strong 3D structure, probably required for adequate cardiac 
functioning (33) while the elastic fibers contribute significantly to myocardial 
mechanics (40).  
The second step was attempted to create hybrid-scaffolds composed solely of 
commercial injectable fibrin sealant incorporating previously solubilized cardiac 
d-ECM. Fibrin sealant was widely used as a helper tool in many surgical fields 
and consists primarily of two components: fibrinogen and thrombin (273). 
Changes in ratio of fibrinogen concentration and thrombin activity can generate 
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gels with different packing density that may influence proliferation, density and 
viability of the cells into the fibrin (273-276). Moreover, fibrin is also commonly 
served as a delivery vehicle in injectable cardiac tissue engineering (277). 
Christman and Lee (277) described an improved cell survival upon the 
transplantation of cells delivered by fibrin glue compared to the injection of cells 
alone. The fibrin glue was also shown to induce neovascularization within the 
ischemic myocardium and reduce infarct expansion (278). 
It was demonstrated that even if the packing density of fibrin gels primarily 
depends on the fibrinogen concentration and thrombin activity (273-276), the 
ratio of F:M can significantly influence the packing density of the gels as well. In 
fact, results demonstrated that increasing fibrin content significantly increases the 
packing density, thus resulting in an uneven incorporation of d-ECM in the gels, 
especially using the two highest F:M ratio (3:1 and 4:1); while increasing the d-
ECM content (F:M 1:4) produced loosely packed gels. Moreover, despite such 
difference, it was observed that fibrin sealant remained liquid for a few seconds, 
the reason why probably d-ECM incorporation was not homogenous in the gels 
and pipetting was tricky. Based on the results obtained, gel formulations with 
highest fibrin (F:M 3:1 and 4:1) and d-ECM content (F:M 1:4) were discarded. 
Since the fibrin gels can be also created by mixing single solutions of fibrinogen 
and thrombin, to prevent fast gelling that inhibited a homogeneous incorporation 
of d-ECM, subsequent hybrid scaffolds were prepared reconstituting the single 
components of fibrin: bovine fibrinogen and thrombin. 
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For the construction of the d-ECM-CPCs incorporating gels, the above 
mentioned components were prepared and mixed using as a reference the 
TISSEEL but modifying the concentration of each single components. Based on 
the results of qualitative and histological analysis of hybrid-scaffolds obtained by 
mixing d-ECM and TISSEEL and considering the issues linked to the constructs 
with highest ratios of F:M or M:F that exhibited an abnormal polymerization, 
low ratios ranging from 1:2 to 2:1 F:M were chosen.  
The choice of F:M ratio to create hybrid-scaffolds is crucial, as it can influence 
the packing density and gelling time. It was observed, in fact, that the density of 
the gels increased with increasing fibrin content and decreased with increasing d-
ECM content.   
Gels with F:M 1:1 ratio were easier to handle, densely packed with a gelling time 
of 8 hours, and these properties could be necessary to ensure consistent formation 
of the gel capable of incorporating accurately both d-ECM and CPCs, in vitro, 
and to treat myocardial infarction in vivo.  
The constructs F:M 1:1 showed that the incorporated cells had a normal 
morphology and were uniformly distributed throughout the entire thickness of 
the gels. This cell distribution is probably due to the well-structured gels, with a 
desirable homogenization among fibrin and matrix that allow cells to migrate 
inside. 
Conversely, the cells incorporated into the gels with F:M ratios of 2:1 and 1:2 
were very often confined to approximately half of the construct. This may 
probably have been due to a high fibrin content that could have inhibited the cell 
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encapsulation (F:M 2:1) or to the high d-ECM content (F:M 1:2) that caused a 
retention of cells in the aqueous surface of the gels.  
As the two main components of fibrin, fibrinogen and thrombin, can be isolated 
from human blood, a fibrin gel was used to create scaffolds. In the future, 
patient-specific scaffolds may be created from the blood of patients in order to 
reduce potential immunogenic response. 
In conclusion, injectable fibrin gels could address the limitation of surgical 
implantation of a robustly engineered cardiac patch and replace the damaged 
myocardial ECM and/or deliver cells directly to the infarcted region. Thus, in the 
future, the use of an in situ injectable scaffold might offer a valuable therapeutic 
option with the advantages of a minimally invasive delivery method and an 
attracting alternate to bio-constructs.  
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6. ICONOGRAPHY 
 
 
 
Fig.1 
Phase contrast microscope image of primary cell culture obtained from 
pathological adult human hearts. 
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Fig. 2 
Immunomagnetic cell sorting: preventive cardiac fibroblasts depletion from 
primary culture (A) and CD117(+) cardiac primitive cells isolation (B-C). 
Fluorescence microscope image of CD117(+) cardiac primitive cells (D). 
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Fig. 3 
Phase contrast microscope image of CPC-P in culture. 
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Table 1. Overview of the decellularization protocol tested. 
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Fig. 4 
Representative macroscopic images of cardiac tissue sectioned by microtome 
before (A) and after decellularization procedure (B). 
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Fig. 5 
Quantification (A) and qualitative analysis (B) of DNA content in sections of 
native (NM) and decellularized cardiac tissue (d-ECM). 
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Fig. 6 
Representative images of Hematoxylin and Eosin (H/E), Sirius Red, Gomori and 
Masson’s Trichrome (MT) stainings on 350 um-thick sections of native (NM) 
and decellularized cardiac tissue (d-ECM). 
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Fig. 7 
Representative images of decellularized (A), lyophilized (B), milled into a 
powder (C), and solubilized (D) myocardium. 
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Fig. 8 
Representative images of Sirius Red, PAS and Mallory stainings of commercial 
fibrin gels at different F:M ratios (1:1, 2:1, 3:1, 4:1 and 1:4). 
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Fig. 9 
Representative images of Hematoxylin and Eosin (HE), MT (Masson’s 
Trichrome, Sirius Red and PAS stainings of fibrin gels by single components: 
fibrinogen and thrombin at different F:M ratios (1:1, 1:2, and 2:1).  
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Fig. 10 
Phase Contrast microscope pictures illustrating CPC embedded in fibrin gels at 
different F:M ratios. A: 2:1, B: 1:2, C: 1:1. 
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